Literature DB >> 15144037

Influenza vaccination of patients with systemic lupus erythematosus.

Ulises Mercado1, Héctor Acosta, Leonel Avendaño.   

Abstract

OBJECTIVE: To determine the safety, the immunogenicity, and the increase of pre-existing autoantibodies in patients with systemic lupus erythematosus (SLE) following influenza vaccination. PATIENTS AND METHODS: Eighteen women with SLE received an inactivated influenza vaccine. Antibody titers were measured before and 4 weeks after vaccination using a standardized hemagglutination inhibition (HAI) assay. Disease activity and antinuclear autoantibodies were determined at study entry, at 4 weeks, and at 8 weeks after vaccination.
RESULTS: After vaccination, the percentage of patients with anti-hemagglutinin antibody levels increased significantly but was lower than in healthy women. Mean antibody titer of patients increased significantly but also was lower than that of controls. Both the mean of disease activity and anti-ds DNA antibody decreased significantly. Adverse effects to the vaccine were mild.
CONCLUSIONS: a) Influenza vaccination appears to be safe; b). Antibody response to influenza vaccination increases significantly for all 3 influenza antigens; c) Specific antibody response is not significantly affected by treatment, age, IgG levels, or disease activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15144037

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  11 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.

Authors:  Sherry R Crowe; Joan T Merrill; Evan S Vista; Amy B Dedeke; David M Thompson; Scott Stewart; Joel M Guthridge; Timothy B Niewold; Beverly S Franek; Gillian M Air; Linda F Thompson; Judith A James
Journal:  Arthritis Rheum       Date:  2011-08

Review 4.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

Review 5.  Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.

Authors:  Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

6.  Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety.

Authors:  Ewa Wiesik-Szewczyk; Magdalena Romanowska; Paweł Mielnik; Hanna Chwalińska-Sadowska; Lidia B Brydak; Marzena Olesińska; Jakub Zabek
Journal:  Clin Rheumatol       Date:  2010-02-07       Impact factor: 3.650

7.  High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

Authors:  Kaval Kaur; Nai-Ying Zheng; Kenneth Smith; Min Huang; Lie Li; Noel T Pauli; Carole J Henry Dunand; Jane-Hwei Lee; Michael Morrissey; Yixuan Wu; Michelle L Joachims; Melissa E Munroe; Denise Lau; Xinyan Qu; Florian Krammer; Jens Wrammert; Peter Palese; Rafi Ahmed; Judith A James; Patrick C Wilson
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

Review 8.  Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.

Authors:  Yafang Huang; Huili Wang; Ling Wan; Xiaoqin Lu; Wilson W S Tam
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 9.  The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease.

Authors:  Yu Bin Seo; Su Jin Moon; Chan Hong Jeon; Joon Young Song; Yoon Kyoung Sung; Su Jin Jeong; Ki Tae Kwon; Eu Suk Kim; Jae Hoon Kim; Hyoun Ah Kim; Dong Jin Park; Sung Hoon Park; Jin Kyun Park; Joong Kyong Ahn; Ji Seon Oh; Jae Won Yun; Joo Hyun Lee; Hee Young Lee; Min Joo Choi; Won Suk Choi; Young Hwa Choi; Jung Hyun Choi; Jung Yeon Heo; Hee Jin Cheong; Shin Seok Lee
Journal:  Infect Chemother       Date:  2020-06

10.  Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis.

Authors:  Zhengfa Liao; Hao Tang; Xiaojia Xu; Yaping Liang; Yongzhen Xiong; Jindong Ni
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.